Delivery Order SPE2DB20D3303-SPE2DB25FA3ST
- Not listed
- The Defense Logistics Agency awarded a $13,027.34 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pens, with an ultimate completion date of September 4, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $21,523.36 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL pen injections. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania facility, which serves as the company's corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors valued at $3,911.93, with performance through August 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $5,834.04 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors. This non-competitive, firm fixed-price delivery order is set to be completed by September 5, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors, with a contract ceiling value of $41,933.14. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors on August 18, 2025, with completion expected by August 19, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's existing pharmaceutical supply framework. The pharmaceutical distributor will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $5,942.03 to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and represents a non-competitive set-aside. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $21,350.96 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injections on September 3, 2025, with completion targeted for September 4, 2025. This is a firm fixed-price delivery order issued under a non-competitive, non-set-aside procurement. The award is performable at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3STDelivery Order
The Defense Logistics Agency (DLA) awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. The award was completed competitively with no set-aside designation and carries an ultimate completion date of September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. This specific delivery order for Zepbound—a GLP-1 receptor agonist used for weight management—reflects the company's role in supplying contemporary pharmaceutical products to support Defense Health Agency and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/16/25 |